Back to Grants
FEDERAL
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
This grant funds research on the mechanisms that influence cancer risk associated with incretin mimetics.
About this program
The grant focuses on understanding how incretin mimetics, a class of medications used to treat diabetes, may impact cancer risk. Researchers are encouraged to explore the biological mechanisms and pathways that could link the use of these drugs to cancer development. This research is crucial for informing clinical practices and ensuring patient safety. The grant is intended for academic institutions, research organizations, and other entities engaged in health-related research.
Eligibility
Eligible applicants include academic institutions and research organizations with a focus on health-related studies.